XtalPi (2228.HK), a leading AI + Robotics platform for drug and material discovery, announced today that RTX-117, an innovative pipeline from its incubator company ReviR Therapeutics (“ReviR”), has reached a major clinical milestone. The candidate has secured Investigational New Drug (IND) approvals from both the China NMPA and the U.S. FDA, marking its official transition into clinical development.
Driven by the outperforming progress of this pipeline and the success of multiple collaborations, XtalPi will receive milestone payments totaling tens of millions of Hong Kong Dollars from ReviR. Under the partnership agreement, XtalPi also maintains rights to future sales royalties and sublicensing revenue sharing, securing long-term upside from the pipeline’s commercialization.
RTX-117 is a prime example of the high-velocity drug discovery enabled by XtalPi’s AI + Robotics platform. It is the first Class 1 innovative drug pipeline in China targeting Charcot-Marie-Tooth (CMT) disease and the only candidate addressing the disease’s underlying pathological pathway at the molecular source in China.
- Clinical Excellence: Preclinical data demonstrates high potency and exceptional target binding, effectively inhibiting the Integrated Stress Response (ISR) and restoring motor function in animal models. The speed of its clinical clearance has significantly exceeded industry expectations.
- Strategic Market Position: Beyond the immediate 2.6 million CMT patients worldwide, RTX-117 possesses massive indication expansion potential. The underlying mechanism could benefit an estimated 50 million people suffering from related disorders.
- Global Competitive Edge: With dual approvals in the world’s two largest pharmaceutical markets, RTX-117 is positioned to disrupt a global CMT treatment market valued at over $10 billion.
The advancement of RTX-117 into the clinic is the first milestone from a broader suite of collaborative pipelines between XtalPi and ReviR. This success validates XtalPi’s ability to systematically output high-quality clinical assets. By empowering incubators with industry-leading AI algorithms and automated infrastructure, XtalPi accelerates the journey from digital design to clinical reality.
About ReviR Therapeutics
ReviR Therapeutics is a clinical-stage global biotechnology company dedicated to combining AI technology with RNA biology to develop highly specific, effective, and safe disease-modifying therapies. Leveraging the profound technical foundations of its proprietary VoyageR platform, ReviR has established a diverse pipeline of innovative drug candidates across the fields of neurological disorders and autoimmune diseases. Its lead small molecule candidate, RTX-117, is currently advancing through clinical trials for Charcot-Marie-Tooth (CMT) disease, with ongoing efforts to expand its indications to other conditions.
